RxDoctor Payments Data

Phuc Quach

Optometrist · Riverside, CANPI 1770617805

Payments from drug & device makers

$821in general payments, 2019–2025

Across 14 payments — averaging $58.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$285
  • Amgen$144
  • Shire North American Group Inc$122
  • Sun Pharmaceutical Industries Inc.$114
  • Aerie Pharmaceuticals, Inc.$87
  • Rxsight Inc$21
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$80498%
  • Gifts$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$821 in reported general payments places this provider in the 55th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$10,005
Medicare patients
72
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine47$30,832
XiidraLifitegrast16$13,155
RhopressaNetarsudil Mesylate16$6,566
Latanoprost716$6,354
LumiganBimatoprost12$5,613
Prednisolone Acetate151$4,811
Cyclosporine17$4,728
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat172$3,288
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,317
Ketorolac Tromethamine89$1,808
Timolol Maleate185$1,461
MoxifloxacinMoxifloxacin Hcl70$1,351
Brimonidine Tartrate50$950
Dorzolamide Hcl27$658
Ofloxacin50$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$285$13,15516 claims
Aerie Pharmaceuticals, Inc.Rhopressa$87$6,56616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,778 optometrist providers in California.

Other optometrist in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →